S
17.83
-0.04 (-0.22%)
| Previous Close | 17.87 |
| Open | 18.08 |
| Volume | 1,422,463 |
| Avg. Volume (3M) | 3,154,080 |
| Market Cap | 13,148,697,600 |
| Price / Book | 28.58 |
| 52 Weeks Range | |
| Earnings Date | 18 Feb 2025 - 24 Feb 2025 |
| Diluted EPS (TTM) | -0.230 |
| Total Debt/Equity (MRQ) | 7.42% |
| Current Ratio (MRQ) | 8.31 |
| Operating Cash Flow (TTM) | -112.89 M |
| Levered Free Cash Flow (TTM) | -62.82 M |
| Return on Assets (TTM) | -31.47% |
| Return on Equity (TTM) | -73.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Summit Therapeutics Inc. | Bearish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 84.36% |
| % Held by Institutions | 11.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Sep 2024 | 1,084,880 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 44.00 (HC Wainwright & Co., 146.78%) | Buy |
| Median | 31.50 (76.67%) | |
| Low | 23.00 (Citigroup, 29.00%) | Hold |
| Average | 33.33 (86.93%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 19.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 11 Dec 2024 | 30.00 (68.26%) | Buy | 18.77 |
| Jefferies | 06 Dec 2024 | 31.00 (73.86%) | Buy | 18.54 |
| HC Wainwright & Co. | 18 Nov 2024 | 44.00 (146.78%) | Buy | 18.98 |
| 31 Oct 2024 | 44.00 (146.78%) | Buy | 18.59 | |
| JMP Securities | 04 Nov 2024 | 32.00 (79.47%) | Buy | 19.96 |
| Citigroup | 27 Sep 2024 | 23.00 (29.00%) | Hold | 20.89 |
| Stifel | 25 Sep 2024 | 40.00 (124.34%) | Buy | 22.64 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Dec 2024 | Announcement | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 26 Nov 2024 | Announcement | Summit Therapeutics to Present at Upcoming Investor Conferences |
| 21 Nov 2024 | Announcement | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 30 Oct 2024 | Announcement | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 |
| 28 Oct 2024 | Announcement | From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update |
| 23 Oct 2024 | Announcement | Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024 |
| 04 Oct 2024 | Announcement | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Oct 2024 | Announcement | Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |